Oral Antiviral Treatment for Coronavirus Disease (COVID-19) in Patients With Systemic Autoimmune Rheumatic Diseases
Authors' conclusion
These data show a favorable outcome and acceptable safety profile of the 2 oral antiviral therapies MP and NM/R among a high-risk SARD population.
Study context
- Population
- Patients with systemic autoimmune rheumatic diseases (SARDs) followed in 2 tertiary outpatient rheumatology clinics, infected with SARS-CoV-2 between February and August 2022, who received molnupiravir (MP) or NM/R52 females
- Participants
- 74 patients
- Exposure
- Molnupiravir or nirmatrelvir/ritonavir in SARDs
- MPn = 26
- NM/Rn = 48
- Outcome
- Recovery at home without COVID-19-related complications
- Follow-up
- During
Methodological details2 tertiary outpatient rheumatology clinics
- 2 tertiary outpatient rheumatology clinics
Main finding
As reported in the abstract
Recovered at home without COVID-19-related complications (all but 2 patients)
72
97.3%
Presumptive COVID-19 rebound progressing to severe COVID-19
2
Observational data: associations, not effects.
Safety
- Common adverse events (metallic taste, gastrointestinal upset, hypertension) — NM/R
- 4 events
Common adverse events (metallic taste, gastrointestinal upset, hypertension)
- Reported only by patients receiving NM/R; not leading to drug discontinuation
Original publication
Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases. J Rheumatol. Published 15 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →